文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

西方人群幽门螺杆菌根除治疗与胃腺癌风险

Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population.
PubMed 文献 · Gut · 2018-01-30

瑞典全国性人群队列研究纳入2005-2012年95176例接受幽门螺杆菌根除治疗者,随访351018人年,发现胃腺癌风险随时间下降,5-7.5年后低于背景人群(SIR 0.31)。

要点

  • 根除治疗后1-3年胃腺癌SIR为8.65,3-5年为2.02,5-7.5年为0.31。
  • 非贲门胃腺癌相应SIR分别为10.74、2.67和0.43。
  • 根除治疗似乎可抵消西方人群胃腺癌的发生。

核心结论

  • 在西方人群中,幽门螺杆菌根除治疗似乎可抵消胃腺癌和非贲门胃腺癌的发生。

研究设计与样本

  • 瑞典全国性、基于人群的队列研究,纳入2005-2012年接受幽门螺杆菌根除治疗的95176例个体,随访351018人年。

主要发现

  • 随访期间75例(0.1%)发生胃腺癌,69例(0.1%)发生非贲门胃腺癌。
  • 根除治疗后1-3年胃腺癌SIR为8.65(95%CI 6.37-11.46),3-5年为2.02(95%CI 1.25-3.09),5-7.5年为0.31(95%CI 0.11-0.67)。
  • 非贲门胃腺癌相应SIR分别为10.74(95%CI 7.77-14.46)、2.67(95%CI 1.63-4.13)和0.43(95%CI 0.16-0.93)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gastric infection with Helicobacter pylori is a strong risk factor for non-cardia gastric adenocarcinoma. The aim of this study was to assess whether the risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma decreases after eradication treatment for H. pylori in a Western population. DESIGN: This was a nationwide, population-based cohort study in Sweden in 2005-2012. Data from the Swedish Prescribed Drug Registry provided information on H. pylori eradication treatment, whereas information concerning newly developed gastric adenocarcinoma was retrieved from the Swedish Cancer Registry. The risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in individuals who had received H. pylori eradication treatment was compared with the background population of the corresponding age, sex and calendar year distribution, yielding standardised incidence ratios (SIRs) with 95% CIs. RESULTS: During the follow-up of 95 176 individuals who had received eradication treatment (351 018 person-years at risk), 75 (0.1%) developed gastric adenocarcinoma and 69 (0.1%) developed non-cardia gastric adenocarcinoma. The risk of gastric adenocarcinoma decreased over time after eradication treatment to levels below that of the corresponding background population. The SIRs were 8.65 (95% CI 6.37 to 11.46) for 1-3 years, 2.02 (95% CI 1.25 to 3.09) for 3-5 years and 0.31 (95% CI 0.11 to 0.67) for 5-7.5 years after eradication treatment. When restricted to non-cardia adenocarcinoma, the corresponding SIRs were 10.74 (95% CI 7.77 to 14.46), 2.67 (95% CI 1.63 to 4.13) and 0.43 (95% CI 0.16 to 0.93). CONCLUSION: Eradication treatment for H. pylori seems to counteract the development of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in this Western population.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Doorakkers E, Lagergren J, Engstrand L, et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018. PMID: 29382776. doi:10.1136/gutjnl-2017-315363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。